In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Baxter International’s current price ($25.81) exceeds its high-confidence fair value estimate ($17.89), indicating potential overvaluation with a 30.7% implied downside. Poor financial health and negative profitability amplify risk, while high Monte Carlo downside probability (94.4%) and volatility suggest substantial uncertainty. Valuation splits reflect disagreement between negative DCF and strong price/sales, signaling market expectation divergences.